Neoadjuvant and adjuvant radiotherapy (RT) appeared to improve outcomes in patients with localized extremity soft tissue sarcoma (eSTS) in a retrospective study.
Adjuvant RT was associated with improved overall survival (OS), and both neoadjuvant and adjuvant RT were associated with a reduction in the risk of local recurrence.
These results were presented at the Connective Tissue Oncology Society (CTOS) 2021 Annual Meeting by Joanna Szkandera, MD, of the Medical University of Graz in Austria.
The multicenter study included 2184 patients with localized eSTS. In the overall cohort, 45% of patients were women, and the median age at surgery was 61 years (range, 48-72 years).
Patients received neoadjuvant (n=271), adjuvant (n=1349), or no RT (n=564). Due to baseline differences between the groups, dedicated statistical methods were used to avoid confounding, Dr Szkandera said.
In a multivariate analysis, neoadjuvant RT was associated with a significantly lower risk of local recurrence compared with no RT (subhazard ratio [SHR], 0.299; 95% CI, 0.180-0.499; P <.001).
However, there was no significant difference in OS between the groups (hazard ratio [HR], 0.819; 95% CI, 0.603-1.109; P =.196).
Compared with no RT, adjuvant RT was associated with a significantly lower risk of local recurrence (SHR, 0.701; 95% CI, 0.545-0.901; P =.006) and a significantly lower risk of death (hazard ratio, 0.805; 95% CI, 0.684-0.947; P =.009).
Dr Szkandera and colleagues plan to conduct an analysis of distant metastasis as well. She said those data will be presented at the European Musculo-Skeletal Oncology Society (EMSOS) meeting in December 2021.
Disclosures: Dr Szkandera disclosed affiliations with PharmaMar, Roche, Eisai, and Bayer.
Read more of Cancer Therapy Advisor’s coverage of CTOS 2021 by visiting the conference page.
Szkandera J. Neoadjuvant and adjuvant radiotherapy decreases the risk of local recurrence and adjuvant radiotherapy improves overall survival in a multicentre cohort of 2162 extremity soft tissue sarcoma patients. Presented at CTOS 2021; November 10-13, 2021. Abstract 51.